Core Viewpoint - The company announced clinical data for its core product, Tengogatinib, in treating advanced cholangiocarcinoma (CCA) patients at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [1] Group 1: Clinical Data Presentation - Tengogatinib, a novel FGFR inhibitor, shows potential activity in overcoming acquired resistance to previous FGFR inhibitors in CCA patients [1] - The report includes an analysis of circulating tumor DNA (ctDNA) biomarkers to evaluate the efficacy of Tengogatinib in patients with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - The study assessed genomic alterations in patient ctDNA and correlated efficacy based on ctDNA mutation status and patient subgroups [1] Group 2: Ongoing Research - The results support further investigation in ongoing Phase III clinical trials by expanding biomarker sampling for deeper analysis [1]
药捷安康-B于2026年美国临床肿瘤学会胃肠道肿瘤研讨会公布替恩戈替尼单药治疗晚期胆管癌患者的临床数据